Skip to Content
Merck
All Photos(1)

Documents

H0137

Sigma-Aldrich

HT Media Supplement (50×) Hybri-Max

lyophilized powder, suitable for hybridoma, BioXtra

Synonym(s):

HT Supplement, Hypoxanthine-Thymidin (HT) media supplement

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352207
NACRES:
NA.75

product name

HT Media Supplement (50×) Hybri-Max, lyophilized powder, γ-irradiated, BioXtra, suitable for hybridoma

Quality Level

sterility

γ-irradiated

product line

BioXtra

form

lyophilized powder

technique(s)

cell culture | hybridoma: suitable

impurities

endotoxin, tested

storage temp.

−20°C

Application

HT Media supplement is a cocktail hypoxanthine and thymidine qualified for use in hybridoma selection and cell culture applications. HT Media Supplement (50×) Hybri-Max has been used as a supplement in INS-1 β-cells co-culture medium. It is suitable for use as medium for hybridoma cells and as Dulbecco′s Modified Eagle Medium (DMEM) for HeLa S3 and MTH1-KO cells.

Reconstitution

Reconstitute contents of vial with 10 ml sterile cell culture medium. Stock solution is sufficient to prepare 500 ml medium. Final working concentration: 100 μM hypoxanthine, 16 μM thymidine.

Legal Information

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The roles of human MTH1, MTH2 and MTH3 proteins in maintaining genome stability under oxidative stress
Hashiguchi K, et al.
Mutation Research. Fundamental and Molecular Mechanisms of Mutagenesis, 808, 10-19 (2018)
Characterization of an IgG monoclonal antibody targeted to both tissue cyst and sporocyst walls of Toxoplasma gondii
Gondim L, et al.
Experimental Parasitology, 163, 46-56 (2016)
Simulated Cholinergic Reinnervation of beta (INS-1) Cells: Antidiabetic Utility of Heterotypic Pseudoislets Containing beta Cell and Cholinergic Cell
Jiao A, et al.
International Journal of Endocrinology, 2018 (2018)
Kimberly A McCormack et al.
Parasitology research, 118(8), 2409-2417 (2019-06-15)
Human babesiosis, a tick-borne disease similar to malaria, is most often caused by the hemoprotozoans Babesia divergens in Europe, and Babesia microti and Babesia duncani in North America. Babesia microti is the best documented and causes more cases of human
Ellen Young et al.
Cell host & microbe, 27(5), 710-724 (2020-05-15)
The rational design of dengue virus (DENV) vaccines requires a detailed understanding of the molecular basis for antibody-mediated immunity. The durably protective antibody response to DENV after primary infection is serotype specific. However, there is an incomplete understanding of the

Protocols

XTT assay protocol for measuring cell viability, proliferation, activation and cytotoxicity. Instructions for XTT reagent preparation and examples of applications.

MTT assay protocol for measuring cell viability, proliferation and cytotoxicity. Instructions for MTT reagent preparation and examples of applications.

MTT assay protocol for measuring cell viability, proliferation and cytotoxicity. Instructions for MTT reagent preparation and examples of applications.

MTT assay protocol for measuring cell viability, proliferation and cytotoxicity. Instructions for MTT reagent preparation and examples of applications.

See All

Related Content

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service